
Common inspection findings and how to prevent them
Examine the 10 most common regulatory binder deficiencies cited in FDA Form 483 observations and sponsor audits, with root causes, prevention strategies, and cross-references to the course modules that teach each preventive practice.
None of these findings are exotic
I want to begin with an observation that should be unsettling. The 10 findings you are about to study are not obscure regulatory technicalities. They are not edge cases that surface once a decade during an unusually thorough inspection. They are the same findings -- the same basic failures of documentation, version control, and filing discipline -- that appear in FDA Form 483 observations year after year, in sponsor audit reports across therapeutic areas, and in monitoring visit findings at sites from Boston to San Diego.